



A phase 2 study of the first imipridone **ONC201**, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

Supplementary Material



Supplemental Figure 1: Sum of product of diameters of two lesions in patient with objective response by RANO criteria after initiation of ONC201 treatment.



Supplemental Figure 2: DRD2 expression in archival tumor specimen. Exemplary image for DRD2 expression assayed by immunohistochemistry.